Chiesi chooses Bespak HFA valve to deliver Budesonide asthma treatment to Europe
Bespak has announced details of the latest metered dose inhaler (MDI) valve development and manufacturing partnership with the pharmaceutical company Chiesi Farmaceutici.
As part of a long-term project, Bespak is supplying Chiesi with an MDI valve and actuator tailored to its exact requirements for the delivery of Budesonide - an asthma treatment.
Chiesi's Budesonide Modulite formulation has been launched on the German market under the brand name Budiair.
Bespak has been involved in the development of MDI valves for more than three decades and has a breadth of experience that has evolved with the changing needs of the pharmaceutical market.
As the drive for chlorofluorocarbon (CFC)-free metered dose inhalers has increased, Bespak has led the way designing a range of valves that are compatible with HFA (ozone friendly) propellants whilst offering similar or improved performance characteristics over its CFC counterparts. "Chiesi screened a number of different valve design options for use in its Modulite formulation and came to the conclusion that Bespak was the partner of choice," said Paolo Chiesi, VP and R and D director at Chiesi.
"The Bespak team got to the heart of Chiesi's HFA needs.
Our decision to work together was based on the level of technical support offered by Bespak and the excellence in design and understanding demonstrated when evaluating our requirements." "Pharmaceutical companies across Europe are working hard to comply with environmental regulations and the phase-out of CFC propellants," said Chris Hall, head of commercial for pulmonary at Bespak.
"Bespak prides itself on being one of the original champions of the development of HFA valves with the broadest range of marketed product partnerships.
We employ a world class team at the forefront of hardware and drug/device interface technology developments.
We are able to provide partner companies with substantiated advice and customised delivery solutions." "Chiesi is at the vanguard of the development and commercialisation of HFA formulations in Europe utilising Modulite technology.
Beclomethasone HFA is commercialised in several European countries; budesonide HFA - Budiair - is commercialised in Germany and formoterol HFA is in phase III clinical development.
The roll out of all our products in Europe and other countries is in progress," said Alberto Chiesi, president and CEO of Chiesi.
To support its work in the development of HFA valves and MDI's, Bespak has invested in a multi-million pound building programme at its site in Kings Lynn, UK.
Scheduled for completion during 2003, the new state of the art manufacturing facility will extend the company's production capabilities and drive the business forward as a front runner in the development of delivery systems for inhaled therapies.
